Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck & Co. has signed a deal with an undisclosed company to market an authorized generic version of its osteoporosis drug Fosamax.
Subscribe to our email newsletter
Although Merck spokesman Ron Rogers confirmed that a Fosamax-related deal has been signed, he did not divulge details about the deal, maintaining that the details were proprietary.
Fosamax’s key US patent is set to expire on February 6, 2008, which will clear the way for generic competition. Teva Pharmaceutical Industries and Barr Pharmaceuticals are also expected to launch generic copies of Fosamax.